Edition:
United States

Achillion Pharmaceuticals Inc (ACHN.O)

ACHN.O on Nasdaq

3.36USD
22 Nov 2017
Change (% chg)

$-0.07 (-2.04%)
Prev Close
$3.43
Open
$3.45
Day's High
$3.54
Day's Low
$3.34
Volume
1,387,708
Avg. Vol
1,910,491
52-wk High
$5.66
52-wk Low
$2.95

Chart for

About

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the... (more)

Overall

Beta: 1.61
Market Cap(Mil.): $472.85
Shares Outstanding(Mil.): 137.86
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 200.71 15.46
EPS (TTM): -- -- --
ROI: -- -10.20 11.85
ROE: -- -36.19 15.83

BRIEF-Achillion announces pricing of secondary offering of common stock

* Achillion announces pricing of secondary offering of common stock

Nov 15 2017

BRIEF-Achillion announces proposed secondary offering of common stock

* Achillion announces proposed secondary offering of common stock

Nov 14 2017

BRIEF-Achillion reports preliminary proof-of-concept with ACH-4471 for the treatment of c3g

* Achillion reports preliminary proof-of-concept with ACH-4471 for the treatment of c3g

Nov 14 2017

BRIEF-Achillion says ACH-4471 granted orphan drug designation by FDA

* Achillion announces ACH-4471 granted orphan drug designation by the FDA and positive opinion for orphan drug designation in the european union for the treatment of paroxysmal nocturnal hemoglobinuria

Nov 06 2017

BRIEF-Achillion Q3 loss per share $0.14

* Achillion reports third quarter 2017 financial results and provides update on clinical programs

Nov 01 2017

BRIEF-RTW Investments reports 5.2 pct passive stake in Achillion Pharmaceuticals - SEC filing‍​

* RTW Investments LP reports 5.2 percent passive stake in Achillion Pharmaceuticals Inc as of September 18, 2017 - SEC filing‍​ Source text: (http://bit.ly/2wXrbF8) Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

Sep 28 2017

BRIEF-Achillion announces termination of worldwide collaboration for hepatitis c with Janssen

* Achillion announces termination of worldwide collaboration for hepatitis c with Janssen Further company coverage:

Sep 11 2017

BRIEF-Achillion Pharmaceuticals says Joel Barrish plans to leave co

* Achillion Pharmaceuticals Inc - ‍announced that Joel Barrish, executive vice president and chief scientific officer, plans to leave company

Jul 10 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $35.43 -0.11
Johnson & Johnson (JNJ.N) $137.29 -1.05
Novartis AG (NOVN.S) CHF83.30 -0.25
Merck & Co., Inc. (MRK.N) $54.37 +0.10
Roche Holding Ltd. (ROG.S) CHF246.80 +2.80
Roche Holding Ltd. (RO.S) CHF248.40 +2.80
Abbott Laboratories (ABT.N) $55.80 -0.32
AstraZeneca plc (AZN.L) 5,007.00 -29.00
GlaxoSmithKline plc (GSK.L) 1,302.50 -0.50
Bristol-Myers Squibb Co (BMY.N) $61.14 -0.10

Earnings vs. Estimates